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Warfarin dose requirement varies significantly. We compared the clinically established 
international normalized ratio (INR) -based doses among patients with severe thrombosis 
and/or thrombophilia with estimates from genetic dosing algorithms. 
METHODS 
Fifty patients with severe thrombosis and/or thrombophilia requiring permanent 
anticoagulation, referred to the Helsinki University Hospital Coagulation Center, were 
screened for thrombophilias and genotyped for CYP2C9*2 (c.430C>T, rs1799853), 
CYP2C9*3 (c.1075A>C, rs1057910) and VKORC1 c.-1639G>A (rs9923231) variants. The 
warfarin maintenance doses (target INR 2.0-3.0 in 94%, 2.5-3.5 in 6%) were estimated by the 
Gage and the International Warfarin Pharmacogenetics Consortium (IWPC) algorithms. The 
individual warfarin maintenance dose was tailored, supplementing estimates with 
comprehensive clinical evaluation and INR data. 
RESULTS 
Mean patient age was 47 years (range, 20-76), and BMI 27 (SD 6), 68% being women. Forty-
six (92%) had previous venous or arterial thrombosis, and 26 (52%) had a thrombophilia, 
with 22% having concurrent aspirin. A total of 40% carried the CYP2C9*2 or *3 allele and 
54% carried the VKORC1 -1639A allele. The daily mean maintenance dose of warfarin 
estimated by the Gage algorithm was 5.4 mg (95% CI 4.9-5.9 mg,), and by the IWPC 
algorithm was 5.2 mg (95% CI 4.7-5.7 mg,). The daily warfarin maintenance dose after 
clinical visits and follow-up was higher than the estimates, mean 6.9 mg (95% CI 5.6-8.2 mg, 
p<0.006), with highest dose in patients having multiple thrombophilic factors (p<0.03). 
CONCLUSIONS 
In severe thrombosis and/or thrombophilia, variation in thrombin generation and 
pharmacodynamics influences warfarin response. Pharmacogenetic dosing algorithms seem 
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What is already known about this subject 
 Effective warfarin dose has high inter-individual variability, owing in part to genetic 
variations in CYP2C9 and VKORC1 
 Warfarin dosing algorithms accounting for genetic and clinical factors may improve 
warfarin therapeutic efficacy, diminishing thromboembolic and bleeding 
complications 
 Among thrombophilia patients, risks for complications are higher 
 
What this study adds 
 Thrombophilia patients are significantly younger than the warfarin using patients on 
average 
 Dosing algorithms seem to underestimate the daily warfarin maintenance dose among 










Vitamin K antagonists (VKAs) impair the synthesis of vitamin K-dependent coagulation 
factors (II, VII, IX and X) by inhibiting the conversion of vitamin K epoxide to its active 
form via the vitamin K epoxide reductase complex (VKOR). Therefore, warfarin and other 
VKAs are used as anticoagulants for treatment or prevention of thromboembolism and in 
association with atrial fibrillation (AF), prosthetic heart valves and thrombophilia. To reach 
the efficient and safe level of anticoagulation, warfarin dosing is individually tailored, and 
regular follow-up is required by laboratory measurements of International Normalized Ratio 
(INR) based on the prothrombin time with the Owren reagent [1]. The average daily warfarin 
dose for all indications is approximately 5 mg, while individual doses may vary even more 
than 10-fold [1,2] 
 
Many factors, including, patient diet, smoking, alcohol use, other medications and genetic 
variants influence warfarin dose requirement [3,4]. It is common practise to start warfarin 
with a fixed dose and tailor the individual dose with INR monitoring. With this approach, the 
time to achieve INR treatment target level might be prolonged in patients at the either 
extremes of the dose requirements. Clinical algorithms aim at predicting the required 
warfarin dose, facilitating the achievement of the INR target level. The common factors 
affecting warfarin dose in the algorithms include: age, race, body surface area, smoking, 
amiodarone and statin use [5]. 
 
Genetic variants influence the efficacy of warfarin by either a pharmacokinetic or 
pharmacodynamic mechanism [6]. Warfarin is a racemic mixture of the S- and R-
enantiomers. The pharmacologically more active S-warfarin is metabolized mainly by 
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CYP2C9, and common CYP2C9 variants, such as CYP2C9*2 (c.430C>T, rs1799853), and 
CYP2C9*3 (c.1075A>C, rs1057910), impair S-warfarin metabolism, reducing warfarin dose 
requirement [7]. In addition, variations of the VKORC1-gene impact the activity of the 
VKOR enzyme, and the VKORC1-variant c.-1639G>A (rs9923231) increases warfarin 
sensitivity [8,9]. Both the CYP2C9 and VKORC1 variants are common among individuals of 
Caucasian ancestry and contribute to the individual warfarin dose requirement [10-14]. The 
common VKORC1 and CYP2C9 variants account for up to 27% and 18%, respectively, of the 
variability in stable warfarin dose requirement among Caucasians [6,11]. 
 
Patient's genetic profiling can be used to predict warfarin dosage and multiple algorithms 
incorporating both genotypic, and clinical data exist to predict warfarin doses [6],according to 
the Gage algorithm and the International Warfarin Pharmacogenetics Consortium (IWPC) 
algorithm. They are commonly adopted for this purpose in clinical practice, and are available 
at warfarindosing.org. [1,15]. Pharmacogenetic dosing algorithm for warfarin has been shown 
to reduce the time to reach the stable dose, improve the percent time in therapeutic range 
(TTR) and decrease the number of episodes with an INR above 4 in a homogenous European 
population [16]. The potential benefit of using genetic profiling is likely substantial in cases 
of increased risks of 1) bleeding complications or 2) thrombosis, when direct oral 
anticoagulants are not recommended due to the uncertainty in dose responses and drug 
exposure, and 3) when therapeutic warfarin dosages must be reached quickly. Our aim was to 
characterize patients having a history of severe thrombosis and/or thrombophilia, and to 










This was a retrospective, register-based study on patients referred to the Coagulation 
Disorders Unit in the Helsinki University Hospital due to severe thrombosis and/or 
thrombophilia to be treated with long-term or permanent warfarin anticoagulation. Warfarin 
genotyping was routinely performed for patients in whom permanent anticoagulation was 
indicated, and thus retrospective analysis of the data was possible. Genetic testing for single 
nucleotide polymorphisms (SNPs) affecting warfarin metabolism has been available for 
clinical use since October 2007. Ethics board was consulted, and ethics permit was not 
requested due to the register-based nature of the study, as mandated by the Finnish law [17]. 
Patient data were pseudonymized and patients were not contacted. The Helsinki University 
Hospital research permit was granted for the research protocol (decision number 20/2018). 
Patients referred during 2009-2018 were assessed for inclusion in the study. At least one of 
the following criteria had to be met for inclusion: thrombosis at a young age (under 50 years), 
strong family history of thrombosis, known severe thrombophilia in laboratory screen 
(phospholipid antibodies, antithrombin, protein C or S deficiency, FV Leiden or FII G20210A 
variant homozygosity or combined heterozygosity for the last two), unusual site of 
thrombosis, multiple spontaneous thromboses or miscarriages, both arterial and venous 
thromboses, active cancer and thrombosis, valvular replacement or other cardiac 
insufficiency predisposing to thrombosis. These criteria indicate permanent anticoagulation 
and were based on the recommendations on testing for thrombophilia [18,19]. Altogether 50 
patients met the criteria, with 19 patients (38%) meeting a single inclusion criterium, but 31 
patients (62%) carried two or more criteria. Laboratory thrombophilia screen had been 
performed for 47 patients, including thrombin time, lupus anticoagulant, beta-2-glycoprotein 
and cardiolipin antibodies, FV Leiden, FII G20210A variant, antithrombin activity, protein C 
activity, protein S free antigen and FVIII:C assays. Thrombophilia screen had been assessed 
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in 41 patients before, in 4 patients simultaneously with, and in 2 patients after 
pharmacogenetic testing for warfarin. Genotyping for CYP2C9*2, CYP2C9*3 and VKORC1 
c.-1639G>A variants and genotyping for FV Leiden and FII G20210A variant in the 
thrombophilia panel had been performed with an automated cyclic mini-sequencing method 
(HUSLAB, Helsinki University Hospital, Finland). 
 
The INR target level in most patients was set to 2.0-3.0 INR, while 3 patients (6%) with 
valvular replacement had an INR target level of 2.5-3.5. Initially, patients were genotyped for 
warfarin associated SNPs and warfarin dose was estimated with the local algorithm based on 
the study by Wadelius et al [20]. After genotyping, all patients had been called for a clinical 
visit and subsequent follow-up visits. If patient met the INR target the current warfarin dose 
in use already after several weeks of stable dose was recorded (real-life dose). If the INR 
target was not met, the subsequent warfarin dose was recommended based on a combination 
of genotypic, clinical, calculated algorithmic and INR data, where the minimum warfarin 
dose was obtained from the local algorithm. The patient was followed up until a new stable 
dose was achieved. Each patient was followed for several months at the clinic to verify the 
stabilization of the dose needed. This final, prescribed stable warfarin dose was recorded and 
is henceforth referred to as the real-life dose of the patient. Subsequently, the Gage and 
IWPC algorithms were used to estimate warfarin dose based on genetic and clinical data and 
compared with the real-life dose [1,15]. 
 
The different dose estimates were compared with one another using Wilcoxon signed rank 
test, and different patient groups were compared to one another with Kruskal-Wallis H test, 
with IBM SPSS® statistics program (version 22). The median difference and 95% confidence 
intervals were estimated with Hodges-Lehmann test [21]. The differences were considered 
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statistically significant when p was below 0.05. 
 
Nomenclature of targets and ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 




The average age of the patients was 47 years (range 20-76), and the mean BMI was 27 kg/m2 
(SD 6). Of all patients, 24/50 (48%) had thrombosis at age under 50 years. Despite the history 
of thrombosis and/or thrombophilia, four patients (8%) continued smoking. ASA use was 
prevalent, with 11 patients (22%) having ASA concurrent with warfarin due to history of 
arterial thrombosis (Table 1). Most patients, 46 (92%), had thrombosis as the primary 
indication for warfarin treatment, with the remaining four patients (8%) having valvular 
replacement as the primary indication, three of them having the higher INR target level of 
2.5-3.5 due to the replacement in the mitral valve position (Table 2). All the valvular 
replacement patients  also had additional factors predisposing to thrombosis– namely 
arteriosclerosis, pulmonary hypertension, heart malformation or insulin-dependent diabetes. 
In over half of the patients screened in the laboratory, 26 (55%) carried thrombophilia, most 
commonly FV Leiden (24%), while seven patients (14%) had more than one thrombophilia 
(Table 3). Of the patients who had thrombosis 25/46 (54%) presented with a thrombophilia. 
Three patients with valvular replacement as their warfarin indication were not tested for 
thrombophilia, while one of them had an elevated FVIII (>190 IU/dL). Fourteen (28%) 
patients had the reference CYP2C9*1/*1 and VKOCR1 c.-1639GG genotypes, 20 (40%) 
carried either CYP2C9*2, *3 or both and 27 (54%) carried the VKORC1 c.-1639G>A variant 
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(Table 4). None of the patients used the enzyme inhibitor or inducer medicines included in 
the IWPC algorithm. The enzyme inhibitor or inducer medicines included in the algorithm 
are azoles (e.g. fluconazole), amiodarone, sulfonamid, phenytoin, carbamazepine and 
rifampicin. 
Warfarin doses 
Daily warfarin doses estimated by the Gage algorithm (mean 5.4 mg, 95% CI 4.9-6.0 mg, SD 
2.0 mg, range 1.5-9.3 mg) or by the IWPC algorithm (mean 5.2 mg, 95% CI 4.7-5.7 mg, SD 
1.9 mg, range 0.9-8.3 mg) were significantly lower than the observed real-life warfarin dose 
(mean 6.9 mg, 95% CI 5.6-8.2 mg, SD 4.5 mg, range 0.8-30.0 mg). Real-life daily dose 
median difference to Gage algorithm was 1.2 mg (95% CI 0.4-2.0 mg, p=0.005) and median 
difference to IWPC algorithm was 1.4 mg (95% CI 0.5-2.1 mg, p=0.001). The correlation 
between the dose estimates according to various algorithms and the established doses in real-
life was poor (Figure 1). In some patients the real-life warfarin dose requirement was higher 
than predicted, up to 20 mg higher daily dose than that predicted by the algorithms (Figure 2). 
The patient with the highest daily warfarin dose of 30 mg was a 35 yo woman who had DVT 
and FV Leiden mutation. The patient was not overweight (BMI 24), did not smoke and had a 
normal genotype for CYP2C9 and VKORC1. No enzyme inducer medication was present. 
The cause of the very high required warfarin dose remains unknown to us. In particular, the 
real-life warfarin daily dose was higher in patients with two or more admission criteria as 
opposed to patients with a single admission criterion (mean 7.9 mg vs. 5.3 mg, median 
difference 2.0 mg, 95 % CI 0.1-4.0, p<0.03). Warfarin dose requirements were the highest in 
patients after an ischemic stroke without AF, valvular replacement, or deep vein thrombosis 
(Table 2), however, these differences did not reach statistical significance (p=0.22). Statin 








The pharmacogenetic IWPC and Gage dosing algorithms significantly under-predicted the 
actual stable warfarin doses in these highly thrombogenic patients. In some trials, the use of 
genotyping among AF patients in the dose estimation has reached the therapeutic warfarin 
levels faster, and the bleeding risk is diminished compared with the conventional dosing 
[1,22,23]. These include the randomized controlled trial (RCT) EU-PACT, in which a 
homogenous European population was studied [24]. To the best of our knowledge, this is the 
first study to examine warfarin dose in young patients with severe thrombosis and/or 
thrombophilia. The previously published studies with young patients (<50 years) have been 
patients with valvular replacement or FV Leiden heterozygous mutation [25-28]. In our 
study, we included only those forms of thrombophilia, which indicate permanent 
anticoagulation therapy, and FV Leiden heterozygosity solely was not an inclusion criterion – 
instead homozygosity or double heterozygosity with FII mutation was required. Currently, 
however, the algorithms accounting for genotypic and clinical factors in comparison with the 
algorithms accounting for the clinical factors only, have not shown consistent results 
favouring genotypic algorithms. In the RCT COAG, in a heterogenous population (27% were 
people of African ancestry) the genetic data added to the clinical algorithm did not improve 
treatment outcome, while in the Gage trial, genotype -guided dosing improved outcome with 
regard to thrombosis [5,22,29]. In the highly thrombogenic patients, the accurate initial dose 
estimation might improve outcome, as risks for thrombotic complications are higher, albeit 
heparin is used until the INR target is well reached. Here, the average daily warfarin dose in 
our thrombotic or thrombophilic patients, was on average 1.9 mg higher than in the literature 
including patients with all warfarin indications (6.9 mg vs. 5 mg) [1]. Our results are 
consistent with a recent meta-analysis, where it was reported that with daily warfarin doses of 
over 7 mg, the dose prediction algorithms underestimated the maintenance dose [30]. In our 
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study, the patients with more than one admission criteria, had significantly higher warfarin 
dose requirement than those with only one admission criterion, highlighting the increased 
thrombogenic potential. It also seemed that the valve replacement patients had a higher dose 
demand, corresponding to the increased INR target range of 2.5-3.5, but patients with the 
history of non-AF ischemic stroke or deep vein thrombosis and pulmonary embolism as well 
seemed to need a higher than average warfarin dose, although statistical significance was not 
reached due to small sample size. Yet, the current dose prediction algorithms, validated in AF 
patients, seem to underestimate the required warfarin dose in thrombogenic patients as a 
group, and especially in patients with multiple thrombogenic factors. It has been shown, that 
in patients with antiphospholipid antibody syndrome, the warfarin dose requirement is 
increased, relative to inherited thrombophilias and irrespective of the VKORC1 and CYP2C9 
genotype, suggesting that among thrombophilia patients factors other than those accounted 
for in the dose algorithms impact the warfarin dose [31]. It has been shown, that in cardiac 
surgery patients, novel pharmacokinetic-pharmacodynamic models may improve dosing 
accuracy, particularly at the early stage of dosing (before steady state), taking into account 
the previous doses and INR responses [32]. However, in comparison with our patient 
population, cardiac surgery may influence the mechanisms of coagulation and hemodynamics 
in distinct manners. 
 
Thrombophilias significantly increase the risk of venous thromboembolism, with VTE risk 
increased by up to 6-fold with antiphospholipid antibodies, 5-fold with increased FVIII:C 
levels, 5-50 times increased with AT deficiency, which confers the highest risk, 5 times with 
protein S and C deficiencies, 3-5 times with a heterozygous FV Leiden variant, and 2 times 
with a heterozygous FII G20210A variant [33-37]. In this study, only four (8%) of the 
patients tested for thrombophilia had AT, PC or PS deficiency, which carry the highest 
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thrombotic risk. The typical warfarin treatment target of INR is 2.0-3.0 applies also in these 
detected thrombophilia patients according to the laboratory panel. 
 
Good quality warfarin management is essential due to the otherwise increased complication 
risks. As the typical TTR in all warfarin patients are only approximately 64%, vigilance is 
required with these patients, keeping in mind that the best results are usually achieved in 
warfarin self-management patients (up to 72% TTR) [38]. Thrombophilia patients express 
enhanced responses in thrombin generation assays, likely explaining the higher warfarin dose 
requirement in these patients [39-43]. 
 
Patients were young, on average 47 years of age, whereas in all indications, most warfarin 
patients are over 60 years of age [44].  Increasing age has been associated with decreasing 
warfarin doses, which is appreciated in the dosing algorithms. Although the pharmacokinetics 
of warfarin is similar in young and elderly adults, older patients have lower average weight, 
increasing their warfarin sensitivity, and also the prothrombin time ratio is increased, while 
adjusted to warfarin dose, suggesting increased pharmacodynamic effects as well [44,45]. 
BMI influences the mean daily warfarin dose, although large interindividual variations exist 
within a BMI group [46]. In our limited sample, with mean BMI only moderately elevated, 
no effect of BMI was observed on the warfarin dose requirement. The effect of age and BMI 
(through body surface area) are included in the Gage and IWPC algorithms [1,15]. However, 
in our study cohort, significantly younger than most warfarin users, the model did not achieve 
the actual real life dose requirement. 
 
The limitations of this study include the restricted sample size of 50 patients due to a single-
site nature of this study. The study was exploratory without power calculations, but 
 
 
This article is protected by copyright. All rights reserved. 
 
 
significant differences between algorithms were identified [47]. The findings need to be 
confirmed in a larger patient populations to enable firmer conclusions. While warfarin 
indications were recorded (Table 2), in the small subgroups we were unable to analyse the 
effect of the clinical indication to warfarin dosing. Another major limitation is, that neither 
the clinician, nor the patient was blinded to the warfarin dose, or to the results of the 
pharmacogenetic analysis. This might have impacted the warfarin prescription, but on the 
other hand, this directly reflects the real-life practice. The strengths include the highly 
thrombogenic non-AF patient cohort in the need of permanent anticoagulation, in which 
warfarin genotyping has not earlier been systematically evaluated. Warfarin dose was 
estimated through the warfaringdosing.org website using Gage and IWPC algorithms, the 
tools that are available to most clinicians, increasing the implications of this study.  
 
Conclusions 
Currently, the most used pharmacogenetics dosing algorithms underestimate the warfarin 
dose required for effective anticoagulation in thrombogenic young (age less than 50 years) 
patients, particularly those who are at the highest thrombotic risk. A thorough clinical 
assessment is required in these patients for the effective and safe warfarin anticoagulation 
which is deemed lifelong. Whether thrombogenic patients will benefit from the other 
anticoagulation strategies than warfarin remains to be seen in future. Today warfarin, the 
traditional anticoagulation modality, is recommended for these patients based on its 
longstanding experience [48]. 
 
Acknowledgements 
We thank RN Maria Patronen and RN Salla Valtonen in the Coagulation Disorders Unit for 




This article is protected by copyright. All rights reserved. 
 
 
Conflicts of interest statement: 




1. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, 
Gage BF, Kimmel SE, et al. Estimation of the warfarin dose with clinical and 
pharmacogenetic data. N Engl J Med 2009;360:753-764. 
2. James AH, Britt RP, Raskino CL, Thompson SG. Factors affecting the maintenance dose 
of warfarin. J Clin Pathol 1992;45:704-706. 
3. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. 
Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 
2005;165:1095-1106. 
4. Nathisuwan S, Dilokthornsakul P, Chaiyakunapruk N, Morarai T, Yodting T, 
Piriyachananusorn N. Assessing evidence of interaction between smoking and warfarin: a 
systematic review and meta-analysis. Chest 2011;139:1130-1139. 
5. Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, et al. A 
pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 
2013;369:2283-2293. 
6. Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, et al. Clinical 
Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-
Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther 2017;102:397-404. 
7. CYP2 family: CYP2C9. Last modified on 16/09/2015. Accessed on 26/02/2019. 
IUPHAR/BPS Guide to pharmacology. 2015; Available at: 
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1326. 
Accessed 02/26, 2019. 
8. Oxidoreductases: vitamin K epoxide reductase complex subunit 1. Last modified on 
05/02/2016. Accessed on 26/02/2019. IUPHAR/BPS Guide to pharmacology. 2016; 
Available at: 
http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2645. 
Accessed 02/26, 2019. 
 
 
This article is protected by copyright. All rights reserved. 
 
 
9. Alexander SPH, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, et al. The 
Concise Guide to pharmacology 2017/18.. Br J Pharmacol 2017;174 (Suppl 1):S1-S446. 
10. Daly AK, Day CP, Aithal GP. CYP2C9 polymorphism and warfarin dose requirements. 
Br J Clin Pharmacol 2002;53:408-409. 
11. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, et al. The largest 
prospective warfarin-treated cohort supports genetic forecasting. Blood 2009;113:784-792. 
12. Owen RP, Gong L, Sagreiya H, Klein TE, Altman RB. VKORC1 pharmacogenomics 
summary. Pharmacogenet Genomics 2010;20:642-644. 
13. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of 
VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 
2005;352:2285-2293. 
14. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, et al. Genetic 
variation in eleven phase I drug metabolism genes in an ethnically diverse population. 
Pharmacogenomics 2004;5:895-931. 
15. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, et al. Use of 
pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin 
Pharmacol Ther 2008;84:326-331. 
16. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A 
randomized trial of genotype-guided dosing of warfarin. N Engl J Med 2013;369:2294-2303. 
17. Finnish Information Centre for Register Research   
Applying for permission to use register data from THL or other agencies under the Ministry 
of Social Affairs and Health. Available at: https://rekisteritutkimusen.wordpress.com/data-
protection-and-permissions/application-to-thl-or-msh/. Accessed 03/02, 2019. 
18. Connors JM. Thrombophilia Testing and Venous Thrombosis. N Engl J Med 
2017;377:1177-1187. 
19. Eichinger S. Cancer associated thrombosis: risk factors and outcomes. Thromb Res 
2016;140 Suppl 1:S12-7. 
20. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, et al. Association 
of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007;121:23-
34. 
21. Hodges J,L.Jr, Lehmann E,L. Estimates of Location Based on Rank Tests. Ann Math 
Statist 1963;34 
22. Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, et al. Effect of 
 
 
This article is protected by copyright. All rights reserved. 
 
 
Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among 
Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial. JAMA 
2017;318:1115-1124. 
23. Tse G, Gong M, Li G, Wong SH, Wu WKK, Wong WT, et al. Genotype-guided warfarin 
dosing vs. conventional dosing strategies: a systematic review and meta-analysis of 
randomized controlled trials. Br J Clin Pharmacol 2018;84:1868-1882. 
24. Pirmohamed M, Wadelius M, Kamali F, EU-PACT Group. Genotype-guided dosing of 
vitamin K antagonists. N Engl J Med 2014;370:1764-1765. 
25. Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, Hu XJ, et al. Validation of VKORC1 
and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in 
Chinese patients. Pharmacogenet Genomics 2009;19:226-234. 
26. Wang M, Lang X, Cui S, Fei K, Zou L, Cao J, et al. Clinical application of 
pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after 
rheumatic valve replacement: a randomized and controlled trial. Int J Med Sci 2012;9:472-
479. 
27. Harikrishnan S, Koshy L, Subramanian R, Sanjay G, Vineeth CP, Nair AJ, et al. Value of 
VKORC1 (-1639G>A) rs9923231 genotyping in predicting warfarin dose: A replication 
study in South Indian population. Indian Heart J 2018;70 Suppl 3:S110-S115. 
28. Nahar R, Saxena R, Deb R, Verma IC. Pharmacogenetic typing for oral anti-coagulant 
response among factor V Leiden mutation carriers. Indian J Hum Genet 2012;18:326-331. 
29. Kimmel SE. Warfarin pharmacogenomics: current best evidence. J Thromb Haemost 
2015;13 Suppl 1:S266-71. 
30. Saffian SM, Duffull SB, Wright D. Warfarin Dosing Algorithms Underpredict Dose 
Requirements in Patients Requiring >/=7 mg Daily: A Systematic Review and Meta-analysis. 
Clin Pharmacol Ther 2017;102:297-304. 
31. Ames PRJ, Margaglione M, Ciampa A, Colaizzo D, Ferrara F, Iannaccone L, et al. 
Increased warfarin consumption and residual fibrin turnover in thrombotic patients with 
primary antiphospholipid syndrome. Thrombosis Research 2011;127(6):595-599. 
32. Xue L, Holford N, Ding XL, Shen ZY, Huang CR, Zhang H, et al. Theory-based 
pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international 
normalized ratio: influence of body size, composition and genotype in cardiac surgery 
patients. Br J Clin Pharmacol 2017;83:823-835. 
33. Jenkins PV, Rawley O, Smith OP, O'Donnell JS. Elevated factor VIII levels and risk of 
 
 
This article is protected by copyright. All rights reserved. 
 
 
venous thrombosis. Br J Haematol 2012;157:653-663. 
34. Zeng W, Tang L, Jian XR, Li YQ, Guo T, Wang QY, et al. Genetic analysis should be 
included in clinical practice when screening for antithrombin deficiency. Thromb Haemost 
2015;113:262-271. 
35. Bucciarelli P, Rosendaal FR, Tripodi A, Mannucci PM, De Stefano V, Palareti G, et al. 
Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, 
protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative 
family study. Arterioscler Thromb Vasc Biol 1999;19:1026-1033. 
36. Folsom AR, Cushman M, Tsai MY, Heckbert SR, Aleksic N. Prospective study of the 
G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and 
incidence of venous thromboembolism. Am J Hematol 2002;71:285-290. 
37. Reynaud Q, Lega J, Mismetti P, Chapelle C, Wahl D, Cathébras P, et al. Risk of venous 
and arterial thrombosis according to type of antiphospholipid antibodies in adults without 
systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmunity 
Reviews 2014;13:595-608. 
38. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on 
anticoagulation control: a systematic review and metaregression. Chest 2006;129:1155-1166. 
39. Luna-Zaizar H, Gonzalez-Moncada AI, Padilla-Lopez EL, Ramirez-Anguiano AC, 
Pacheco-Moises FP, Velasco-Ramirez SF, et al. Thrombin generation and international 
normalized ratio in inherited thrombophilia patients receiving thromboprophylactic therapy. 
Thromb Res 2015;136:1291-1298. 
40. Hemker HC, Al Dieri R, De Smedt E, Beguin S. Thrombin generation, a function test of 
the haemostatic-thrombotic system. Thromb Haemost 2006;96:553-561. 
41. Al Dieri R, de Laat B, Hemker HC. Thrombin generation: what have we learned? Blood 
Rev 2012;26:197-203. 
42. Dargaud Y, Beguin S, Lienhart A, Al Dieri R, Trzeciak C, Bordet JC, et al. Evaluation of 
thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb 
Haemost 2005;93:475-480. 
43. Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low 
risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 
2006;296:397-402. 
44. Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Aging and the 
anticoagulant response to warfarin therapy. Ann Intern Med 1992;116:901-904. 
 
 
This article is protected by copyright. All rights reserved. 
 
 
45. Shepherd AM, Hewick DS, Moreland TA, Stevenson IH. Age as a determinant of 
sensitivity to warfarin. Br J Clin Pharmacol 1977;4:315-320. 
46. Mueller JA, Patel T, Halawa A, Dumitrascu A, Dawson NL. Warfarin dosing and body 
mass index. Ann Pharmacother 2014;48:584-588. 
47. Ring A, Schall R, Loke YK, Day S. Statistical reporting of clinical pharmacology 
research. Br J Clin Pharmacol 2017;83:1159-1162. 
48. Moll S. New insights into treatment of venous thromboembolism. Hematology Am Soc 
Hematol Educ Program 2014;2014:297-305. 
 
 
This article is protected by copyright. All rights reserved. 
 
 
Table 1: Characteristics of the 50 patients 
Age, years, mean (range) 47 (20-76) 
Women (%) 34 (68) 
Height, cm, mean (SD) 168 (11) 
Weight, kg, mean (SD) 75 (19) 
BMI, mean (SD) 27 (6) 
CYP2C9*1/*2, n (%) 8 (16) 
CYP2C9*1/*3, n (%) 7 (14) 
CYP2C9*2/*3, n (%) 5 (10) 
VKORC1 c.-1639G/A genotype, n 
(%) 
17 (34) 
VKORC1 c.-1639A/A genotype, n 
(%) 
10 (20) 
ASA use, n (%) 11 (22) 
Statin use, n (%) 10 (20) 
Smoking, n (%) 4 (8) 
BMI, body mass index; CYP2C9, cytochrome P2C9 gene; VKORC1, vitamin K epoxide 
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Table 2: Warfarin indications, and corresponding predicted warfarin dose estimates 
and real-life stable dose according to the specific indication, n=50 







DVT or PE 33 (66) 5.7 (2.1) 5.4 (1.9) 7.4 (5.0) 
Peripheral arterial 
thrombosis 
4 (8) 3.2 (0.9) 3.2 (1.0) 3.9 (2.9) 
Atrial fibrillation and 
ischemic stroke 
2 (4) 3.0 (1.1) 2.8 (1.6) 2.5 (2.0) 
Other ischemic stroke 2 (4) 5.6 (1.7) 5.7 (1.8) 7.7 (3.7) 




4 (8) 5.9 (1.7) 5.7 (1.3) 7.4 (3.7) 
† Other thrombosis included paroxysmal nocturnal hemoglobinuria, thrombi of vena cava, of 
sinus cavernosus, of portal and hepatic vein; DVT, deep vein thrombosis; IWPC, 




This article is protected by copyright. All rights reserved. 
 
 
Table 3: Thrombophilias detected in the laboratory screen, n=50 
Thrombophilia n (%) 
FV Leiden heterozygous 10 (20) 
FV Leiden homozygous 2 (4) 
FII variant heterozygous 4 (8) 
FV Leiden and FII variant, both 
heterozygous 
2 (4) 
Antiphospholipid antibodies 7 (14) 
AT, PC or PS deficiency 4 (8) 
Elevated FVIII:C 6 (12) 
No thrombophilia in screening 21 (42) 
Thrombophilia screen not done 
(valvular cases) 
3 (6) 
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CYP2C9 *1/*1 14 12 4 30 
*1/*2 4 1 3 8 
*1/*3 3 3 1 7 
*2/*3 2 1 2 5 
Total 23 17 10 50 
 
 





Figure 1: The correlation with the real-life dose was poor with both dose estimates: 
Gage estimated dose, R2=0.26; IWPC estimated dose, R2=0.29. The highest daily real-











Figure 2: Mean daily real-life-dose was 6.9 mg, with Gage estimated dose 5.4 mg and 
IWPC estimated dose 5.2 mg. Real-life dose was higher than the dose estimates 
(p<0.006). Average dose (bold line) and individual patient doses are shown. The highest 
daily real-life dose of 30 mg is not visible in the figure. IWPC, International Warfarin 
Pharmacogenetics Consortium 
 
 
 
